AR083205A1 - Metodo para tratar el crecimiento celular anomalo - Google Patents
Metodo para tratar el crecimiento celular anomaloInfo
- Publication number
- AR083205A1 AR083205A1 ARP110103580A ARP110103580A AR083205A1 AR 083205 A1 AR083205 A1 AR 083205A1 AR P110103580 A ARP110103580 A AR P110103580A AR P110103580 A ARP110103580 A AR P110103580A AR 083205 A1 AR083205 A1 AR 083205A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell growth
- abnormal cell
- inhibitor
- met
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Inhibidores de c-Met/HGFR y VEGF para tratar el crecimiento celular anómalo en mamíferos. En particular, métodos para tratar mamíferos que tienen cáncer. En particular, métodos para tratar mamíferos que tienen cáncer metastásico. En particular, métodos para inhibir el cáncer metastásico.Reivindicación 1: Un método para tratar el cáncer en un mamífero que necesita dicho tratamiento, caracterizado porque comprende la etapa de administrar una cantidad terapéuticamente eficaz de un inhibidor de VEGF y una cantidad terapéuticamente eficaz de un inhibidor de c-Met/HGFR. Reivindicación 4: El método de acuerdo con cualquiera de las reivindicaciones 1 - 3, caracterizado porque el inhibidor de VEGF se selecciona del grupo que consiste en sunitinib, SU-14813, PF-337210, bevacizumab y axitinib. Reivindicación 10: El método de acuerdo con cualquiera de las reivindicaciones 1 - 9, caracterizado porque el inhibidor de c-Met/HGFR es crizotinib o PF-04217903.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38793410P | 2010-09-29 | 2010-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083205A1 true AR083205A1 (es) | 2013-02-06 |
Family
ID=44800074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103580A AR083205A1 (es) | 2010-09-29 | 2011-09-28 | Metodo para tratar el crecimiento celular anomalo |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2012072140A (es) |
| AR (1) | AR083205A1 (es) |
| TW (1) | TW201217361A (es) |
| WO (1) | WO2012042421A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| RU2737765C2 (ru) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
| WO2014152959A1 (en) * | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| JP2015057974A (ja) * | 2013-09-18 | 2015-03-30 | 学校法人順天堂 | 患者原発性大腸癌の個別化転移モデルマウスの作製方法 |
| RU2016141385A (ru) * | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| JP6741596B2 (ja) * | 2015-01-16 | 2020-08-19 | 中外製薬株式会社 | 併用医薬 |
| JP2016155776A (ja) * | 2015-02-24 | 2016-09-01 | 学校法人兵庫医科大学 | 抗腫瘍効果増強剤および抗腫瘍剤 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923986A (en) | 1987-03-09 | 1990-05-08 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance K-252 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| DE69718472T2 (de) | 1996-07-13 | 2003-11-06 | Glaxo Group Ltd | Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | ANGIOGENESIS INHIBITORS |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1005470B1 (en) | 1997-08-22 | 2007-08-01 | AstraZeneca AB | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| CN101328186A (zh) | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
| BR9910792A (pt) | 1998-05-29 | 2002-01-29 | Sugen Inc | Inibidores de quinase protéica 2-indolinona substituìda com pirrol |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| DK1255536T3 (da) | 1999-12-22 | 2006-10-30 | Sugen Inc | Indolinonderivater til modulation af c-kit-tyrosinproteinkinase |
| DE122008000002I1 (de) | 2000-02-15 | 2008-04-17 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| ES2453164T3 (es) | 2001-08-15 | 2014-04-04 | Pharmacia & Upjohn Company Llc | Cristales que incluyen una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, procedimientos para su preparación y sus composiciones |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| PL372302A1 (en) | 2002-02-15 | 2005-07-11 | Pharmacia & Upjohn Company | Process for preparing indolinone derivatives |
| HN2003000272A (es) | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
| AR042042A1 (es) | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
| US20040209937A1 (en) | 2003-02-24 | 2004-10-21 | Sugen, Inc. | Treatment of excessive osteolysis with indolinone compounds |
| PT2476667E (pt) | 2003-02-26 | 2014-09-18 | Sugen Inc | Compostos de aminoheteroarilo como inibidores da proteína quinase |
| WO2005023765A1 (en) | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
| AU2004275842B2 (en) | 2003-09-26 | 2010-09-02 | Exelixis Inc. | c-MET modulators and methods of use |
| MXPA06003661A (es) | 2003-10-02 | 2006-06-05 | Pharmacia & Upjohn Co Llc | Sales y polimorfos de un compuesto de indolinona sustituido con pirrol. |
| US20050182122A1 (en) | 2003-11-20 | 2005-08-18 | Bello Carlo L. | Method of treating abnormal cell growth using indolinone compounds |
| AU2004309166B2 (en) | 2003-12-23 | 2008-02-21 | Pfizer Inc. | Novel quinoline derivatives |
| PT1786785E (pt) | 2004-08-26 | 2010-05-21 | Pfizer | Compostos amino-heteroarilo enantiomericamente puros como inibidores da proteína quinase |
| EP2289892B1 (en) | 2005-02-09 | 2012-08-22 | ArQule, Inc. | Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer |
| RU2007135167A (ru) | 2005-03-23 | 2009-03-27 | Пфайзер Продактс Инк. (Us) | Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака |
| RU2007141654A (ru) | 2005-05-12 | 2009-05-20 | Пфайзер Инк. (US) | Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат |
| WO2006123223A1 (en) | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| MX2008001838A (es) | 2005-08-08 | 2008-04-09 | Pfizer | Sales y polimorfos de un inhibidor de vegf-r. |
| TW200714620A (en) | 2005-08-30 | 2007-04-16 | Zeon Corp | Cycloolefin addition polymer, its composite and molding, and optical material |
| EP1963302B1 (en) | 2005-12-05 | 2013-02-27 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| BRPI0717320A2 (pt) | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| MX2009010761A (es) | 2007-04-05 | 2009-10-28 | Pfizer Prod Inc | Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos. |
| US20110039856A1 (en) | 2007-11-29 | 2011-02-17 | Pfizer Inc. | Polymorphs of a c-met/hgfr inhibitor |
| EP2288383A1 (en) * | 2008-05-14 | 2011-03-02 | Amgen, Inc | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| TW201019961A (en) * | 2008-10-17 | 2010-06-01 | Genentech Inc | Combination therapy |
-
2011
- 2011-09-15 WO PCT/IB2011/054042 patent/WO2012042421A1/en active Application Filing
- 2011-09-28 JP JP2011212522A patent/JP2012072140A/ja not_active Withdrawn
- 2011-09-28 TW TW100135093A patent/TW201217361A/zh unknown
- 2011-09-28 AR ARP110103580A patent/AR083205A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012072140A (ja) | 2012-04-12 |
| TW201217361A (en) | 2012-05-01 |
| WO2012042421A1 (en) | 2012-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083205A1 (es) | Metodo para tratar el crecimiento celular anomalo | |
| ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
| CY1118696T1 (el) | Μεθοδοι για θεραπεια διαχυτης ενδοαγγειακης πηξης με παρεμποδιση εξαρτωμενης απο masp-2 ενεργοποιησης συμπληρωματος | |
| MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
| AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
| EA201490814A1 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| EA201592182A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| EA201491008A1 (ru) | Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита | |
| MX355648B (es) | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| TR201819092T4 (tr) | Serin proteaz inhibitörleri olarak multi-sübstüte edilmiş aromatik bileşikler. | |
| EA201491694A1 (ru) | Лечение рака ингибиторами tor киназы | |
| EA201100609A1 (ru) | Способы лечения воспаления | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| UY33221A (es) | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA | |
| EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
| AR099707A1 (es) | Composiciones y métodos para tratar trastornos renales | |
| MX2015013703A (es) | Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas. | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
| MX369609B (es) | Una composición para usarse en el tratamiento de cáncer deficiente en nmt2. | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| EA201101639A1 (ru) | Ингибиторы митохондриальной активности клеток, инициирующих рак, и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |